What’s Happening
Chatter
- CRA Travel
- Sick ants invite self-sacrifice to save colony, scientists discover: “Hey, come and kill me”
- Toward a biological theory of everything
- pixel editing for redacting image uploads
- Base resume revamp
- Comment faire de la culture cellulaire in vitro?
- Which location in the US is best for clinical research?
- What interview questions will they ask for trainee drug safety associate role in novo nordisk
- “Issue with Faint DNA Bands After Gel Electrophoresis
- CRC struggling
- Get $50 for Clinical Trial Site Staff Insights!
- Success Story Despite This Godforsaken Market
- Success Story Despite This Godforsaken Market
- Career Advice
- Lawmakers dig in on biopharma manufacturing with bill proposing US center of excellence
Charts
Research
Longboard Pharma and Bexisaserin
Longboard Pharma was acquired by H. Lundbeck A/S on Oct 14, 2024 at about $60 per share. The deal valued Longboard at roughly $2.6 billion dollars, which made it one of the highest returning biopharma stocks of the year. That acquisition price, if closed on, will deliver an 800% return for shareholders YTD at time of writing. Today we will take a closer look at this clinical stage pharma company, and its primary asset, bexicaserin.
…